The patient has a rash on her cheeks and nose with sparing of the nasolabial folds, in addition to involvement of the dorsal ...

The Lupus Foundation of America (LFA) and its funded researchers will unveil the latest advances in patient-centered research at the American College of Rheumatology (ACR) Convergence 2025 meeting in ...

FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as shown in phase II NOBILITY and phase III REGENCY data1,2Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody ...

The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of ...

Roche’s Gazyva/Gazyvaro receives US FDA approval for the treatment of lupus nephritis: Basel Wednesday, October 22, 2025, 10:00 Hrs [IST] Roche announced that the US Food and Dr ...

Congenital heart block, sometimes referred to as cardiac neonatal lupus, is a rare but potentially life-threatening condition ...

Basel: Roche has announced that the US Food and Drug Administration (FDA) has approved Gazyva/Gazyvaro (obinutuzumab) for the ...

Gazyva/Gazyvaro is the only anti-CD20 antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study2 Lupus nephritis is a debilitating condition that ...

The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving standard therapy, ...

Today, Heart & Stroke released the latest five-year update to its Canadian Guidelines for Cardiopulmonary Resuscitation (CPR) and Emergency Cardiovascular Care (ECC). Among the key updates is a ...

Investing.com -- The U.S. Food and Drug Administration (FDA) has approved Roche Holding AG’s (SIX:RO) Gazyva/Gazyvaro ...